Issues in treatment-resistant depression.

Area of Science:

• Psychiatry and Mental Health
• Clinical Pharmacology
• Neuroscience

Background:

• Major depressive disorder (MDD) is a prevalent and disabling condition with substantial societal and economic costs.
• Treatment resistance is a common challenge in managing MDD, despite available therapeutic options.
• Variability in defining antidepressant response and remission complicates the assessment of treatment-resistant depression (TRD).

Purpose of the Study:

• To discuss operational definitions for antidepressant response, nonresponse, partial response, and remission in the context of MDD.
• To review current pharmacotherapy strategies for TRD, including augmentation, combination, and switching therapies.
• To explore alternative and emerging treatment modalities for patients with treatment-resistant depression.

Main Methods:

• Literature review of pharmacotherapy, electroconvulsive therapy, and psychotherapy for treatment-resistant depression.
• Analysis of data from controlled clinical trials supporting various treatment approaches.
• Discussion of emerging nonpharmacologic therapies currently under investigation.

Main Results:

• Limited data from controlled clinical trials support current pharmacotherapy augmentation, combination, and switching strategies for TRD.
• Electroconvulsive therapy and psychotherapy are established alternative treatment options for TRD.
• Several novel nonpharmacologic therapies are being investigated for their efficacy in treating TRD.

Conclusions:

• Standardized operational definitions are crucial for understanding and managing treatment-resistant depression.
• Current evidence for pharmacotherapy strategies in TRD is limited, necessitating exploration of diverse treatment options.
• Achieving complete remission is the ultimate therapeutic objective for patients with major depressive disorder, including those with treatment resistance.